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Abstract
Background: Many older people have chronic knee pain. Both topical and oral non- steroidal anti-
inflammatory drugs (NSAIDs) are commonly used to treat this. Oral NSAIDS are effective, at least
in the short term, but can have severe adverse effects. Topical NSAIDs also appear to be effective,
at least in the short term. One might expect topical NSAIDs both to be less effective and to have
fewer adverse effects than oral NSAIDs. If topical NSAIDs have fewer adverse effects this may
outweigh both the reduction in effectiveness and the higher cost of topical compared to oral
treatment. Patient preferences may influence the comparative effectiveness of drugs delivered via
different routes.
Methods: TOIB is a randomised trial comparing topical and oral ibuprofen, with a parallel patient
preference study. We are recruiting people aged 50 or over with chronic knee pain, from 27 MRC
General Practice Research Framework practices across the UK. We are seeking to recruit 283
participants to the RCT and 379 to the PPS. Participants will be followed up for up to two years
(with the majority reaching one year). Outcomes will be assessed by postal questionnaire, nurse
examination, laboratory tests and medical record searches at one and two years or the end of the
study.
Discussion: This study will provide new evidence on the overall costs and benefits of treating
chronic knee pain with either oral or topical ibuprofen. The use of a patient preference design is
unusual, but will allow us to explore how preference influences response to a medication. In
addition, it will provide more information on adverse events. This study will provide evidence to
inform primary care practitioners, and possibly influence practice.
Published: 07 November 2005
BMC Musculoskeletal Disorders 2005, 6:55 doi:10.1186/1471-2474-6-55
Received: 25 August 2005
Accepted: 07 November 2005
This article is available from: http://www.biomedcentral.com/1471-2474/6/55
© 2005 Cross et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Musculoskeletal Disorders 2005, 6:55 http://www.biomedcentral.com/1471-2474/6/55
Page 2 of 11
(page number not for citation purposes)
Background
Osteoarthritis (OA) is a common condition, particularly
in older people[1]. Around 36% of those aged over 50 suf-
fer from knee pain[2-4], half of whom have severe diffi-
culty with physical function or severe pain[5]. The vast
majority of patients who seek care receive it in primary
care. Since much of this pain is due to OA, and the only
treatment convincingly shown to slow progression of OA
is surgery, primary care management should target pain
and disability[6]. Analgesics and non steroidal anti-
inflammatory drugs (NSAIDs) are the most commonly
prescribed drugs for knee pain in older people.
NSAIDs for knee pain
Oral NSAIDs reduce pain in those with knee osteoarthri-
tis[7]. Despite the risks of gastro-intestinal side effects,
renal insufficiency, hepatic toxicity, exacerbation of
asthma, sodium retention, raised blood pressure and
resistance to anti-hypertensive drugs[8], oral NSAIDs are
widely used for the symptomatic treatment of OA in older
people[9]. In 2003 over 20 million prescriptions for oral
NSAIDs, at a cost of over £250 million, were dispensed in
England[10]. There are few data on the direct, indirect and
intangible costs and cost offsets from using NSAIDs in
older people; the personal and economic costs of manag-
ing adverse effects are, however, large. Around 40% of
hospital admissions with upper gastrointestinal bleeding,
and 40% of associated deaths in older people, are related
to NSAID use[11].
Topical NSAIDs
An alternative to using oral NSAIDs is to use topical
NSAIDs, which may have fewer side effects as a result of
lower serum concentrations[12]. In 2003, 4.5 million pre-
scriptions for topical antirheumatics were dispensed in
England, at a cost of £25 million[10].
There are data to show that topical applications of ibupro-
fen achieve therapeutic concentrations in deep compart-
ments[13]. Thus they could have pharmacological effects
on peri-articular and intra-articular structures, as well as
having effects through peripheral and central sensitisa-
tion[14]. The continued popularity of rubefacients, with
no active ingredient, supports the idea that patients'
responses to topical NSAIDs may also be partly mediated
through the act of rubbing the affected part and the
patients' expectation of receiving a benefit[15].
A meta-analysis of studies using topical NSAIDs con-
cluded that they were more effective than placebo oint-
ments for chronic musculoskeletal disorders at up to two
weeks of use[16]. Another meta-analysis considering
longer periods of use found that topical NSAIDs were no
more effective than placebo at three or four weeks of
use[14].
If :
a) the combined effect of NSAID in the ointment, the act
of rubbing, and the patients' expectation of benefit pro-
duces an effect on pain and disability, and 
b) topical NSAID preparations have fewer adverse effects
compared to oral preparations,
then topical preparations may be preferable to oral ones
as routine treatment for older patients with knee OA, as
there will be fewer side effects in those whose pain can be
managed effectively by topical NSAIDs.
Choice of NSAID and chronic knee pain to study
There are compelling reasons for choosing ibuprofen to
treat chronic knee pain when comparing topical and oral
NSAIDs:
• different NSAIDs appear to be equally effective in the
treatment of knee OA[17].
• a meta-analysis of the risk of gastrointestinal side effects
found that low-dose ibuprofen had the lowest risk com-
pared to other NSAIDs [18].
• the reduction in risk of gastrointestinal side effects is
similar when comparing high-dose ibuprofen with either
low-dose oral ibuprofen or with Cox-II inhibitors[19].
Ibuprofen is widely used both orally and topically for the
treatment of osteoarthritis. In 2003 there were five million
and one million prescriptions issued for oral and topical
ibuprofen respectively, in England. These represent 25%
of oral and 22% of topical NSAID prescriptions.
• most chronic knee pain is thought to be secondary to
osteoarthritis[20]. There are problems in diagnosing OA,
in that many older people have x-ray changes of OA with-
out experiencing symptoms, and even when x-ray changes
are present, OA may not be the cause of their pain.
• x-ray evidence of OA has little impact on pragmatic gen-
eral practice management of knee pain in older people;
indeed, most patients are treated without any x-rays being
taken.
Objective of study
The main objective of this study is to evaluate the benefits
and risks of oral and topical ibuprofen in older people
with chronic knee pain. A secondary objective is to
explore patients' attitudes to medication for knee pain.
Health economic objectives
We will look at the cost effectiveness of topical and oral
ibuprofen in terms of three key research questions:BMC Musculoskeletal Disorders 2005, 6:55 http://www.biomedcentral.com/1471-2474/6/55
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1. What are the societal costs and benefits of implement-
ing the programme, in terms of the impact the pro-
gramme has upon the NHS, patient and other service
providers?
2. What is the cost effectiveness of the programme over a
one-year period and how is this influenced by treatment
compliance?
3. What is the predicted long-term cost effectiveness of the
programme based on the likelihood and extent of major
and minor side effects?
Methods
The randomised controlled trial (RCT) will evaluate, for
people with chronic knee pain, the difference in effective-
ness (primarily at one year), and the difference in side
effects from general practitioner treatment with oral ver-
sus topical ibuprofen over the follow up period. As this is
a study lasting over a year, we expect that many patients
will change their treatment if pain relief is inadequate. If
they do need to change, they are asked to keep to the same
route, oral or topical, if possible. For this reason, we
expect that the pain outcome at one year will reflect some,
but not all, of the difference in effectiveness of the treat-
ments.
Consequently this study has elements of both a difference
study and an equivalence study[21]. Our hypothesis is
that the oral treatment will have greater side effects.
Patients for whom the oral and topical treatment would
be equally effective at pain relief will be expected to have
more side effects if they are allocated to oral rather than
topical treatment. Patients who persist with topical treat-
ment that is less effective than oral treatment may have
more pain and fewer side effects. Patients who rapidly
change if topical is less effective than oral are likely over
the longer term to have similar side effects and pain to
patients already on oral treatment. Because patients can-
not be expected to remain on inadequate treatment, an
intention-to-treat analysis is more appropriate than an
on-treatment analysis. The latter would be required for a
typical equivalence study. Understanding the results
depends crucially on the pattern of combined benefits
and harms from the two treatments. However, as the com-
bined effects require a judgement to be made of the rela-
tive value of pain relief and side effects, we will first
analyse pain and side effects separately. For pain we will
be considering whether the outcomes are different or
equivalent; for side effects we are interested only if they
are different. Then we will seek to demonstrate whether
overall patient outcomes (benefits and harms) are better,
or worse, if general practitioners advise treatment with
either topical or oral NSAIDs, for a range of weightings of
pain and side effects.
Patient preference study
In addition to the RCT, there is a parallel patient prefer-
ence study (PPS). This will enhance the external validity of
the study because:
a) we can establish whether strong preferences affect the
relative outcomes. The results of RCTs may not be gener-
alisable if those with strong preferences for a particular
treatment are excluded[22].
b) the difficulties of recruiting trial participants from pri-
mary care are well known. Allowing those who have a
preference for one treatment to be recruited to a PPS will
provide more observational data.
c) an RCT would have to be very large to identify any dif-
ferences in serious adverse events. Including data col-
lected from the PPS will provide further information.
Additionally we will:
a) explore study participants' perceptions of treatment
using depth interviews with a theoretical sample of partic-
ipants. This integration of qualitative data into the inter-
pretation of the quantitative data may provide insights
into any unexpected or anomalous findings[23,24].
b) collect information on treatment preferences prior to
randomisation.
Participant inclusion and exclusion criteria
The inclusion and exclusion criteria are as follows:
Inclusion criteria
• aged 50 or over.
• have ever had pain in or around the knee on most days
for at least a month and have experienced knee pain for
more than three months out of the preceding year.
• GP consultation, or treatment, for knee pain in the pre-
ceding three years.
• informed consent.
• agreement to use chosen or allocated treatment.
• GP agreement to prescribe oral/topical ibuprofen.
• ability to complete postal questionnaires.
Exclusion criteria
• peptic ulceration (past or current).
• current moderate or severe indigestion.BMC Musculoskeletal Disorders 2005, 6:55 http://www.biomedcentral.com/1471-2474/6/55
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• previous severe adverse reaction to NSAIDs.
• hypertension (systolic BP of 155 mm of Hg or more or
a diastolic BP of 105 mm of Hg or more).
• uncontrolled heart failure.
• creatinine > 140 mmol/L.
• abnormal liver function sufficient to contraindicate use
of NSAIDs (as liver function tests performed and reference
ranges vary between different laboratories, this decision is
at the discretion of the participant's GP).
• GP request not to include.
• serious psychological or psychiatric disorders (including
dementia).
• previous knee replacement/s or awaiting knee surgery.
• inflammatory arthropathy.
• pain referred from hip or back.
• serious injury within six months.
• currently on anticoagulants or oral steroids.
• anaemia (Hb <12.4 g/L for men or <11.8 g/L for
women).
• disseminated malignancy.
To meet the American College of Rheumatologists' (ACR)
clinical criteria for osteoarthritis of the knee, patients need
to have knee pain, as defined for this study, and meet
three out of the following six criteria [25]:
• aged over fifty.
• less than 30 minutes morning stiffness.
• crepitus.
• bony tenderness.
• bony enlargement.
• no palpable warmth.
Measuring the proportion of our sample meeting each of
these criteria will allow us to describe our sample more
accurately, and assess whether any of these criteria affect
outcome.
Participant identification and recruitment
Location
The study is taking place in 27 practices (plus two pilot
practices) from the Medical Research Council General
Practice Research Framework GPRF[26]. We sought to
select practices that were nationally representative in
terms of region, deprivation and type of locality (inner
city/urban/suburban/rural).
Identifying potential participants
In order to maximise recruitment we are using three
approaches to identify potential participants:
a) searching electronic medical records within general
practices for patients aged 50 or over who have consulted
with OA or knee/leg pain in the preceding 5 years.
b) searching electronic prescribing databases for all
patients aged 50 or over who have received a prescription
for oral/topical NSAIDs or a rubefacient over the preced-
ing year.
c) during the study recruitment period, GPs are asked to
notify the practice research nurse when potentially eligi-
ble patients consult.
After training, the practice-based research nurses perform
a search on the practice computer using MIQUEST[27].
This program, which was obtained from the National
Health Service Information Authority, will search nearly
all GP software in current use. The search selects patients
over 50 who either have a diagnosis of osteoarthritis or
knee pain recorded within the last 5 years, or who have
received a prescription for NSAIDs or a rubifacient over
the last 12 months.
The output from this search generates a comma-delimited
file, on a floppy disk, containing the patients' name and
address data. A bespoke software program generates study
ID numbers, personalised approach letters and partici-
pant registers for the research nurse. This program is sent
out to practices on a laptop computer, with a printer and
pre-printed study paperwork. The nurses use this compu-
ter, and the data generated from the practice computer
system, to print names and addresses on the invitation let-
ters. After printing, all patient data are removed from the
study computer. This approach minimises access to the
patient records for research purposes, ensures all patient-
identifiable data remains within the practice until explicit
consent has been given for it to be released to the study
team, and automates the production of study paperwork.
Initial approach questionnaire
The list of potential participants is screened by the GP and
those whom it would be inappropriate to approach, forBMC Musculoskeletal Disorders 2005, 6:55 http://www.biomedcentral.com/1471-2474/6/55
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example those patients with terminal illness or serious
psychological disorders, are removed. Invitations to par-
ticipate, trial information sheets, questionnaires to screen
for eligibility and expression of interest forms are sent
from and returned to the practice.
Initial assessment
The practice-based research nurse contacts interested
patients who, from the initial approach questionnaire,
appear eligible. At the initial assessment:
a) the trial is explained to the potential participant.
b) eligibility is confirmed.
For those potential participants who are still eligible and
interested:
a) blood pressure and peak expiratory flow rate are meas-
ured.
b) blood is collected for full blood count, renal function,
liver function and serum ferritin.
c) arrangements are made for a medical assessment prior
to a baseline assessment one-two weeks later.
d) potential participants are asked not to use any topical
or oral NSAIDs for one week before baseline assessment.
Medical assessment
Between the initial and baseline assessments potential
participants attend for a brief clinical assessment by a gen-
eral practitioner, to identify components of the ACR clin-
ical criteria for knee OA. The general practitioner also
confirms, in light of the laboratory results, the potential
participant's eligibility for the study, and agrees that he or
she will be willing to prescribe either oral or topical ibu-
profen for this potential participant. A patient with con-
traindications to either oral or topical ibuprofen cannot
enter the study, either in the RCT or the PPS.
Baseline assessment
Eligible and interested patients return one to two weeks
later to complete baseline questionnaires, to have base-
line blood pressure, peak expiratory flow and forced expir-
atory volume measured, and to complete consent forms.
Immediately after baseline assessment those consenting
to join the RCT are randomised. All participants are pro-
vided with a starter pack of their chosen/allocated treat-
ment when randomised to ensure that they can start
treatment immediately.
The assessment procedures are the same for patients in the
RCT and PPS. Figure 1 shows the recruitment process,
with the calculated recruitment targets.
Allocation and protection from bias
A remote telephone randomisation service, separate from
the main study team, uses computer-based randomisation
to register patients joining the study and to allocate RCT
participants to treatment groups. Randomisation is strati-
fied by practice, severity of pain, age and source of patient.
The main study team are blind to participants' chosen/
allocated treatment. The trial statistician, who is not
involved in data collection, has information on chosen/
allocated treatment for the data monitoring and ethics
committee.
At a practice level the study is not blinded. The main out-
come measures are all based on self-completed question-
naires; clinical outcomes are measured at baseline, 1 and
Figure 1BMC Musculoskeletal Disorders 2005, 6:55 http://www.biomedcentral.com/1471-2474/6/55
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2 years (or end of study if sooner). Blood is analysed in
the practice's usual NHS laboratories. Blood pressures are
the average of three readings using a Compact Dinamap
(Johnson & Johnson). Respiratory function is an average
of three readings made using a Clements Clarke one flow
tester ATS 94 spirometer. Mortality data are collected from
practices and the NHS central registry. Prescribing,
selected diagnostic and hospital admission data are col-
lected from patient records by practice nurses.
Interventions
The two interventions being compared are the GP's rec-
ommendation (either a prescription or advice to get an
over-the-counter preparation) to use either topical or oral
ibuprofen. For those whose chosen/allocated treatment is
oral ibuprofen, practices are asked to use no more than
1.2 g per day. Treatments for knee pain other than NSAIDs
may be used as each patient's doctor thinks appropriate.
Adherence with chosen/allocated treatment will be
assessed using:
1. a summary of GP prescriptions issued for the trial par-
ticipants, converted into Average Daily Quantities for top-
ical/oral ibuprofen and other topical/oral NSAIDs.
2. participant self-report of the number of times they have
used pain-killing tablets or rubbing ointments in the
month previous to each of the questionnaires, plus infor-
mation in the same questionnaires on whether they have
changed treatment during follow-up.
Follow-up
Follow-up is organised centrally. Postal questionnaires
consist of the same package of instruments collected at
baseline. Participants are sent postal questionnaires three,
six, 12 and 24 months after randomisation. One year and
two years after randomisation participants are asked to
visit the practice to have their blood pressure and respira-
tory function measured and blood taken for full blood
count, serum ferritin, creatinine and liver function tests.
The medical records are examined one year after randomi-
sation to identify unplanned hospital admissions, and
after two years (or at the end of the study) to collect health
service activity data and confirm reported changes in med-
ication and adverse effects. Follow-up procedures are
summarised in Figure 2.
We are taking the following steps to keep loss to follow up
to a minimum:
1. there are two reminders for each follow up question-
naire, the second by recorded delivery.
2. participants who are unable to attend surgery for
annual follow-up will be visited at home by the practice
nurse.
3. participants are flagged at NHS central registry to ensure
that we identify all deaths, and changes of general practi-
tioner. This will also allow us to locate participants who
have moved house for follow-up.
4. participants who have withdrawn from treatment con-
tinue to be followed up, with their consent.
Qualitative study
Depth interviews will be conducted on a sample of partic-
ipants during the study. A theoretic sampling strategy will
be used to explore the theory that 'older' people's beliefs
about the efficacy of topical and oral ibuprofen are shaped
by their social role as non-economically productive mem-
bers of the social order[28]. The theory to be explored pos-
tulates that older people do not act as consumers in
respect of their use of topical and oral ibuprofen, but
rather accept at face value 'expert' knowledge from health
professionals.
A theoretic sample will be generated. Informants will be
selected based on their age, severity of pain, treatment
choice/allocation, and occurrence of adverse events. These
interviews will be recorded, transcribed and analysed
using the principles of theory- informed qualitative anal-
Figure 2BMC Musculoskeletal Disorders 2005, 6:55 http://www.biomedcentral.com/1471-2474/6/55
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ysis to establish the veracity of the constructed theoretical
model[29]. To avoid any possibility that the interviews
could, themselves, affect the participants' responses to the
main outcome measures, data from these participants will
not be included in the main analysis.
Outcome measures
Data collection is the same for the RCT and PPS. The out-
come measures include measures of pain and disability,
quality of life, use of medication and adverse events.
Health economic data will also be collected.
Patient pain or quality of health outcomes
Primary outcome measure
• the Western Ontario and McMaster Universities Oste-
oarthritis Index (WOMAC) questionnaire, which meas-
ures pain and disability in the preceding 48 hours[30].
Secondary outcome measures
• the postal version of the Chronic Pain Grade[31], which
measures pain and disability over the preceding six
months.
• the EQ5D[32,33], a measure of health-related quality of
life.
• the SF-36 version 2[34], a different measure of health
related quality of life.
• a question assessing satisfaction with treatment.
Major possible adverse effects
The proportion who die or have an unplanned hospital
admission will be presented. A trial powered to show a
difference in individual major adverse events would be
unfeasibly large. For example, in the control arm of a trial
of misoprostol for patients taking NSAIDs 1% of patients
had a serious upper gastrointestinal complication over six
months[35]. The rates of serious gastrointestinal compli-
cation in the control groups of the CLASS[36] and
VIGOR[37] studies of Cox-2 inhibitors compared with
NSAIDs were 0.6% and 1% respectively.
Ascribing causality for individual events to the medication
will not usually be possible.
Deaths will be identified by practices when records are
withdrawn and by flagging of records at NHS central reg-
istry. Unplanned hospital admissions will be identified
from patient-completed questionnaires and annual med-
ical record examination. Cause of admission will be ascer-
tained from medical record. If necessary, the unplanned
nature of an admission will be confirmed by the practice
nurse contacting the participant.
Minor possible adverse effects
A composite binary measure of minor adverse events will
be developed, consulting with general practitioners using
the Delphi technique. We will define these as changes in
selected parameters serious enough for a change of treat-
ment to be advised. We will collect data on the following
parameters indicative of 'minor side effects'; these will be
reported individually, and they may also contribute to the
overall composite measure:
• iron deficiency or iron deficiency anaemia. data from
the Framingham study show that the prevalence of iron
deficiency in NSAID users, measured by serum ferritin
(2.7%), is over twice the prevalence of iron deficiency
anaemia (1.2%) in a healthy elderly population[38]. Fer-
ritin may therefore be a useful proxy for occult gastrointes-
tinal bleeding.
• new diagnosis of hypertension or failure of existing anti-
hypertensive treatment or increase in blood pressure dur-
ing follow up.
• New diagnosis of asthma/chronic obstructive pulmo-
nary disease (COPD), or a new prescription of either a
beta-2 agonist or a steroid inhaler, or a 15% fall in peak
flow. Explicit new diagnoses will be identified from the
medical record. In a previous GPRF study, recording of
new diagnoses of asthma in general practice record was
found to be unreliable[39]. For this reason the issue of a
beta-2 agonist inhaler to someone who has not had one
in the preceding year will be used as an indicator of a new
diagnosis of asthma/COPD. Deterioration in asthma/
COPD control will be considered present if a patient is
initiated on a steroid inhaler. Deterioration in lung func-
tion measures will also be used.
• Renal impairment The upper limit of the normal range
for creatinine in older people is 160 mmol/L[40]. This is
higher than in a younger population. Patients with a cre-
atinine >140 mmol/L at baseline will not be included.
• Heart failure Few GPs have access to echocardiography
to confirm the diagnosis of heart failure. For this reason
any new diagnosis of heart failure in the practice records
will be included.
• Indigestion An increase in recorded indigestion by more
that one category on a five-point Likert scale.
Compliance
• decision to stop NSAIDs for any reason during the study
period.
• use of other analgesics during the study period.BMC Musculoskeletal Disorders 2005, 6:55 http://www.biomedcentral.com/1471-2474/6/55
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Health economic outcomes
The two main outcomes that arise from medication are
alleviation of knee pain balanced against the adverse
effects of medication. The main HE analysis uses a com-
bined summary measure of quality of life using the EQ-
5D and the SF-6D[41]. It is recognised, however, that our
summary quality of life measures, taken at different time
intervals, may not adequately capture adverse effects from
medication due to their fluctuating and temporary nature.
Initially we had proposed to model 'any presumed link'
between minor and major effects and death. This no
longer seems appropriate given that exposure to adverse
effects of medication is likely to lead to a discontinuation
or switching of medication. We will instead conduct sec-
ondary analysis based upon the clinical measures of pain
and adverse effects. If the pain levels are similar in the two
treatments, and only the adverse effects are statistically
different, we will use the composite binary measure of
minor adverse events to calculate the 'number needed to
harm' for both oral and topical medication[42]. This cal-
culation gives the number of patients who must receive
medication before we expect to see one harmful case of
adverse effects. If both pain and adverse effects are statis-
tically different between the two medications, we will
attempt to combine the measures of pain and adverse
effects, informed by patients' preferences for medication
based on patients' a) compliance to the regime and b)
switching to the alternative medication. This secondary
analysis will also draw upon the qualitative study of
patients' attitudes towards medication.
Costs
Costs will be obtained by recording units of resources, e.g.
GP consultations, drug purchases and hospital attend-
ance, used in both groups and applying a tariff to each
type of unit. Health service usage will be based upon
patients' self-reported usage, validated against medical
records. Where possible, local cost tariffs will be used with
national sources as a comparator. The costs to participants
and their families will be obtained from the patient ques-
tionnaire.
The incidence of serious adverse effects caused by ibupro-
fen is such that a much larger trial is required to identify
an important difference between the two groups. How-
ever these events may have large financial and other costs.
Particular care, therefore, will be made in measuring the
financial impacts of side effects.
Sample size
The sample size estimate is based on the primary efficacy 
measurement at one year
Previous work has shown minimum differences in
WOMAC pain and disability scales perceptible to patients
are around 10–12 mm on a 100 mm visual analogue
scale[43]. Typical standard deviations for the change
between baseline and follow-up in knee OA trials are
around 22 mm. The results will be presented for the dif-
ference between groups in the change from baseline in
WOMAC mean score with their 95% confidence intervals.
To show a difference of 10 mm with 90% power and 5%
significance we need analysable data on 103 subjects in
each group. Assuming a 75% follow-up rate at one year,
this means we need to recruit 275 participants to the RCT.
This will also show equivalence to within 10 mm at 80%
power.
Early recruitment data for the PPS indicate a 3:1 prefer-
ence for topical compared to oral treatment; allowing for
this imbalance, we need to recruit 368 participants to the
PPS to achieve 90% power.
When the study was first started, it was planned that we
would recruit to both RCT and PPS from all participating
practices. However early recruitment data indicated that
twice as many people would join the PPS when compared
to the RCT, suggesting that we would overshoot our PPS
recruitment target whilst not reaching the more important
RCT recruitment target. For this reason, with the agree-
ment of the funders, the trial steering committee and the
data monitoring and ethics committee, we are recruiting
to the RCT only in the last seven practices to join the
study.
It is usual in equivalence studies to do an on-treatment
analysis rather than an intention-to-treat analysis. How-
ever, as this study is testing two approaches to managing
knee pain, it was agreed that an intention-to-treat analysis
would be appropriate, although on-treatment analyses of
side effects will also be carried out.
Analysis
Initially the RCT and PPS will be analysed separately. The
primary and secondary outcomes of pain and health sta-
tus, side effects and compliance (which includes drug use
and mode of delivery) will be described and analysed on
an intention-to-treat basis. The first analyses will be on
outcomes or changes in outcomes at one year. This is the
period for which the most substantial amounts of data
will be available. There will also be an on-treatment anal-
ysis of side effects, which will report results for oral or top-
ical treatment both before and after adjusting for other
drug use. Although the data on timing of side effects is
limited, it will be possible to produce estimates of the rate
of side effects and hazard ratios for the effect of the mode
of different treatment as well as for dosage and other pain
killers.
The joint distributions of pain at one year and side effects
at or by one year will be plotted. The effect of a range ofBMC Musculoskeletal Disorders 2005, 6:55 http://www.biomedcentral.com/1471-2474/6/55
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relative utilities of pain and side effects will be incorpo-
rated into the analysis to produce more information on
the relative advantage of the oral vs topical approach.
Prior to any analysis, and blind as to the treatment arm,
we will have checked and validated the data. Rules for
classification of information on side effects, hospital
admissions and drug usage, each of which can come from
a number of sources, will have been set, implemented and
checked. Missing data in the health scores will be dealt
with as recommended in the relevant manuals.
Details of analyses
All results will be presented with 95% confidence inter-
vals.
ITT analyses comparing topical and oral treatment
For binary outcomes, the differences in proportions, as
well as the odds ratio (from unadjusted logistic regres-
sion) will be presented. The effect of any failure of the ran-
domisation will be investigated for the RCT, but
adjustment will be made for the expected difference
between the groups in the PPS using logistic regression.
For ordinal data with 5 categories or fewer the results will
be presented as tables of proportions.
All other scores will be treated as quantitative date and
will be analysed using t-tests or multiple regression.
Normally the change in WOMAC score from baseline
would be the most appropriate measure, adjusting as it
does for baseline pain, but as absolute levels of pain may
be more strongly associated with treatment dose, and
hence side effects, this measure will be included as well. If
the randomisation is successful then both should be unbi-
ased.
Differences in measures of potential side effects will be
used preferentially, although results for absolute values
may be presented.
On-treatment analysis by mode of drug
The information available on drug usage over the year is
not complete. Classification of average daily dose will
incorporate the three measures – prescriptions over the
period, and the measures of drug use over the previous
month and two days as indicated in the questionnaires.
Estimates will be obtained for the period covered by each
questionnaire and over the first year. Where we know a
side effect has resulted in a change of medication during
the time a questionnaire covers, estimates of drug use
prior to the change will be made from the previous ques-
tionnaire (if available) and/or prescribing data as appro-
priate.
The development of a side effect will be analysed using
survival analysis methods allowing for changing predic-
tors. As part of this analysis allowance will be made for
other painkillers being taken by the participants. The pain
killers will already have been classified according to their
likely side effects.
On-treatment analysis of WOMAC scores is unlikely accu-
rately to reflect the treatment effect, as patients with inad-
equate treatment are more likely to have changed
treatment.
Combined analysis of WOMAC and side effects
The joint distributions of the WOMAC score at one year
and side effects will be displayed graphically by study arm.
In order to make judgements on the relative overall bene-
fit of each treatment the results of a) the Delphi study into
GPs' attitudes to side effects, and b) the qualitative study
of patients' attitudes to them will be incorporated as util-
ities in a Bayesian analysis of the relative benefits for a
range of values of the relative importance of pain and side
effects.
If there is a similarity in the relationship between pain and
side effects for the four groups, the relationship will be
modelled.
Sensitivity analyses
The potential effect of withdrawals from the study and
missing data will be investigated. Best and worst case sce-
narios will be given.
Comparison of RCT and PPS results
The effects of treatment (by intention-to-treat) will be tab-
ulated for the two studies. Appropriate multiple analysis
will be performed adjusting for those predictors expected
to be different in the two studies (eg age, sex, attitude to
treatment and possible troublesomeness of knee at base-
line). Tests will be made for potential interaction of type
of study with type of treatment.
The combined outcomes of WOMAC and side effects will
be investigated graphically in the two studies to see
whether the relationship appears to have similar charac-
teristics. If it does, modelling of the relationship to allow
for the different baseline characteristics will be attempted.
Health economics analysis
The study will estimate the distribution of costs and out-
comes of treatment. This will allow us to investigate the
probability that the intervention is cost effective and to
establish a confidence interval around the cost effective-
ness estimate. Given that there is a band of 'uncertainty'
around the measure of adverse effects additional sensitiv-BMC Musculoskeletal Disorders 2005, 6:55 http://www.biomedcentral.com/1471-2474/6/55
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ity analysis will be conducted around this measure to see
the impact on the cost effectiveness result.
The secondary health economics analysis will be based
upon the clinical measures of pain and adverse effects. If
the main difference between topical and oral medications
is that the former produce fewer adverse effects, we can
estimate the cost of preventing adverse effects caused by
oral medication. If the cost of prevention is less than the
cost of treating one episode of adverse effects, then there
is a clear case for preferring the use of topical medication.
If the treatment cost is less than the cost of prevention,
then the decision to implement topical mediation rests on
a view of the value of preventing the pain and suffering
from these adverse effects. The value of this prevention
will be informed by both the Delphi study into GPs' atti-
tudes to side effects and the qualitative study of patients'
attitudes to them. If both pain and adverse effects are sta-
tistically different between the two medications, we will
gauge patients' preference for the medications looking at
a) compliance to the regime and b) switching to the alter-
native treatment regime. This secondary analysis will also
draw upon the qualitative study of patients' attitudes
towards medication[41].
Discussion
Recruitment started in April 2003. By April 2005 we had
completed our recruitment with 276 participants in the
RCT and 288 participants in the PPS. Early follow-up rates
at one year are around 80–85%, suggesting that we will
have ample data for our analyses of the RCT. While the
PPS is a little underpowered, it will provide important
information to the on-treatment analyses of side effects
and effects of compliance.
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